J. Greenbowe

发表

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

Yu Shyr, Xingyi Guo, James X. Sun, 2016, Cancer Immunology Research.

Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.

J. Ross, A. Maitra, V. Miller, 2019, Gastroenterology.

Tumor mutational burden as a potential biomarker for PD1/PD-L1 therapy in colorectal cancer.

James X. Sun, J. Ross, V. Miller, 2016 .

Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.

P. Stephens, J. Ross, S. Ou, 2015, Lung cancer.

Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition

H. Kim, B. Cho, Z. Zheng, 2017, Oncogene.

I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.

S. Ou, V. Miller, Siraj M. Ali, 2015, Lung cancer.

Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing

P. Stephens, R. Yelensky, S. Ou, 2016, Clinical Cancer Research.

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Mark Rosenzweig, Joel Greshock, Doron Lipson, 2015, Cancer discovery.

Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.

P. Stephens, S. Ou, V. Miller, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.

James X. Sun, V. Miller, G. Frampton, 2018, Journal of gastrointestinal oncology.

Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.

W. Bulman, A. Saqi, V. Miller, 2016, Clinical lung cancer.

Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer

James X. Sun, Jing Wang, J. Minna, 2018, Oncotarget.

Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative

S. Paik, Siraj M. Ali, S. Lim, 2016, Oncotarget.

Abstract 1118: Activation of MET via diverse exon 14 skipping mutations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors

Alex M. Fichtenholtz, P. Stephens, R. Yelensky, 2015 .

Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches

M. Ladanyi, A. Drilon, M. Kris, 2015, Clinical Cancer Research.

Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type.

D. Lin, Siraj M. Ali, J. Elvin, 2017, Gynecologic oncology.

Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC

G. Giaccone, J. Gregg, P. Stephens, 2018, PloS one.

Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma.

J. Lacy, M. Nikiforova, Siraj M. Ali, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus

In Seok Yang, Min Goo Lee, Hyo Song Kim, 2016, Oncotarget.

Hybrid capture-based next-generation sequencing (HC NGS) in melanoma to identify markers of response to anti-PD-1/PD-L1.

R. Sullivan, Dennie T. Frederick, J. Sosman, 2016 .

Identification Of Actionable Genomic Alterations In Hematologic Malignancies By a Clinical Next Generation Sequencing-Based Assay

Alex M. Fichtenholtz, S. Armstrong, P. Stephens, 2013 .

Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches

M. Ladanyi, A. Drilon, M. Kris, 2015, Clinical Cancer Research.